Cognoa, a Palo Alto, CA-based digital health company, raised $11.6m in funding.
The funding was provided by existing investor Morningside.
The company, which has raised more than $20m since founding, will use the capital to advance its machine-learning-based technology; support additional clinical validation and the U.S. Food and Drug Administration (FDA) submissions and approvals process; and expand commercialization with employers, payers and clinicians.
Led by Brent Vaughan, CEO, Cognoa leverages machine learning and patient reported outcomes to enable parents and clinicians to take the right action at the right time to support their child’s development, providing a detailed evaluation, identifying whether a child is at risk for delays, such as autism or attention deficit hyperactivity disorder. Cognoa’s assessment has been used by 300,000 families and has been validated in multiple scientific clinical studies. It is based on more than five years of clinical research and validation studies led by Dennis Wall, PhD, at prominent institutions including Harvard Medical School and Stanford Medical School.
The company recently launched Cognoa for Employers, which fits into current healthcare platforms.